{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:06:51Z","timestamp":1781215611497,"version":"3.54.1"},"reference-count":28,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T00:00:00Z","timestamp":1654387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic encephalopathy (HE) is a complication of cirrhosis. Rifaximin, added to lactulose, effectively maintains remission and reduces hospitalizations from HE compared with lactulose alone. Although the clinical evidence supports the use of rifaximin, concerns remain regarding the financial implications and subsequent impact on medication access and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The goal of this study was to determine whether medication access to rifaximin at hospital discharge reduces readmission and office visits related to HE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted in compliance with local institutional review board including cirrhotic patients discharged with a rifaximin prescription for HE. Patients were stratified into 2 groups: those able to obtain rifaximin and those unable to obtain rifaximin upon discharge. The primary outcome was to evaluate the rate of HE recurrence in each group as defined as a composite of readmission or office visit for acute HE within 12 months of discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Access to rifaximin significantly reduced the risk of hospital admission and office visit for acute HE over 12 months. A hospitalization or office visit occurred in 24.5% of patients in the medication access group compared with 50% in the group without medication access. Only 58% of patients had access to rifaximin at discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Rifaximin use was associated with significantly reduced risk of hospitalization and office visits for HE. At discharge, 42% of patients did not have access to rifaximin regardless of being prescribed the medication, identifying that copay is a significant barrier in allowing patients to have access to rifaximin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221100537","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T02:10:03Z","timestamp":1654481403000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1861-7282","authenticated-orcid":false,"given":"Ann Marie","family":"Stoll","sequence":"first","affiliation":[{"name":"Internal Medicine, Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guido","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"},{"name":"Division of Pharmacy Practice and Administration, University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Pence","sequence":"additional","affiliation":[{"name":"Specialty Pharmacy, Department of Pharmacy Services, University of Cincinnati Specialty Pharmacy, UC Health, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-8835","authenticated-orcid":false,"given":"Anthony J.","family":"Gentene","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"},{"name":"Division of Pharmacy Practice and Administration, University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,5]]},"reference":[{"key":"e_1_3_2_2_2","volume-title":"Ferri\u2019s Clinical Advisor 2018 E-Book","author":"Ferri FF.","year":"2017","unstructured":"Ferri FF. Ferri\u2019s Clinical Advisor 2018 E-Book. 1st ed. Amsterdam, the Netherlands: Elsevier; 2017.","edition":"1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.03.019."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23128."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.01.026."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600561."},{"key":"e_1_3_2_7_2","unstructured":"Vilstrup H Amodio P Bajaj J et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL. American Association for the Study of Liver Diseases website. Accessed May 4 2021. https:\/\/www.aasld.org\/sites\/default\/files\/2019-06\/hepaticencephalopathy82014.pdf."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13111."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04808.x."},{"key":"e_1_3_2_11_2","unstructured":"Cardinal Health. United States 2022. Web Archive. Retrieved from the Library of Congress. Accessed March 1 2022. <www.loc.gov\/item\/lcwaN0015520\/>Prescription."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1746-6342.2006.03215.x."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2008.03.009."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9442-4."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(99)80144-5."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21129."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13415."},{"key":"e_1_3_2_18_2","unstructured":"Unsupported Price Increase Report: 2020 Assessment. Institute for Clinical and Economic Review. ICER 2020 Report. Accessed June 1 2021."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.12.019."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16645049."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1590-8658(00)80027-4."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000648."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-013-9383-5."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.947."},{"key":"e_1_3_2_25_2","unstructured":"Nitazoxanide. Lexi-Drugs. Lexicomp. Wolters Kluwer Health Inc. Accessed June 14 2021. http:\/\/online.lexi.com."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.04.009."},{"issue":"8","key":"e_1_3_2_27_2","first-page":"3","article-title":"Emerging issues in gastroenterology and hepatology","volume":"5","author":"Bass NM","year":"2009","unstructured":"Bass NM, Feagan B. Emerging issues in gastroenterology and hepatology. Gastroenterol Hepatol (N Y). 2009;5(8)(suppl 17):3-20.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S146438."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03464.x."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221100537","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221100537","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221100537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:54Z","timestamp":1777375014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221100537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,5]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/10600280221100537"],"URL":"https:\/\/doi.org\/10.1177\/10600280221100537","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,5]]}}}